Suven Life Sciences to participates at 12th Annual C21 BioVentures

Suven Life Sciences, a biopharmaceutical company will be participating at 12th Annual C21 BioVentures TM (C21), at Napa, California, USA from May 25-27, 2010. The company plans to discuss its corporate overview, business strategy, fund raising and partnering activity by presenting their Phase 1 clinical candidate SUVN-502 for cognition in Alzheimer’s and Schizophrenia at the C21 BioVentures 2010 .

C21, the leading conference where early stage innovators, investors and pharma partners come together to do the deals for global partnering as it provides the greatest opportunity for building relationship, facilitating discussions on financing opportunities with an unparalleled opportunity to create new value generating partnerships ,with their  targeted audience of senior executives and industry leaders from pharmaceutical, biotechnology and venture capital communities.

The Company has twelve internally discovered therapeutic drug candidates currently, in pre-clinical stage of development targeting conditions such as ADHD, dementia, depression, Huntington’s disease, Parkinson’s disease and obesity in addition to developmental candidate SUVN-502 for Alzheimer’s disease and Schizophrenia.

Suven Life Sciences, a biopharmaceutical company is focused on discovering, developing and commercializing novel pharmaceutical products.